期刊文献+

包头地区类风湿关节炎患者生活质量及其影响因素分析 被引量:5

Analysis of the quality of life of patients with rheumatoid arthritis and its influential factors in Baotou Area
暂未订购
导出
摘要 目的分析类风湿关节炎患者生活质量的主要影响因素,为提高类风湿关节炎患者生活质量提供依据。方法采用国际通用的评价生活质量的SF-36量表对491例类风湿关节炎患者进行生活质量的调查,同时调查患者的社会经济情况、文化情况,以及患者的个人特征和患病的一般情况。用t检验、χ2检验和逐步回归对每一种影响因素分别进行分析,找出主要影响因素。结果单因素分析显示,患者性别、文化程度、职业、婚姻状况、医疗费用负担形式、反应疾病的活动程度与生活质量的各领域或大多数领域均有关系。多因素分析显示,对患者生活质量的主要影响因素是文化程度、医疗费用、职业和婚姻状况。结论类风湿关节炎患者由于长期病痛的折磨以及治疗的花费,使他们的生活质量明显降低。遏制过高的医疗费用,改善医疗水平,提高人民的健康教育水平,保持心情愉快,是提高类风湿关节炎患者生活质量的关键。 Objective To analyze the main influential factors of the quality of life (QOL) of patients with rheumatoid arthritis (RA), and provide a basis for the improvement of RA patients" QOL. Methods The SF-36 scale evaluating the QOL internationally was adopted to survey 491 RA patients as well as their social and economic status, cultural situa- tion, personal characteristics, and general condition of diseases. Each influential factor was analyzed by t-test, variance analysis, and stepwise regression in order to find out the principal ones. Results On univariate analysis, gender, educa- tional level, occupation, marital status, medical expense form, and active level reflecting the disease were related with all or most areas of the QOL. Further multivariate analysis was performed, and the main factors influencing the QOL were educational level, medical expense, occupation, and marital status. Conclusion Due to long-term torture by dis- ease and medical expense in RA patients, their QOL obviously decreased. The key to better RA patients" QOL is through curbing exorbitant medical cost, improving medical care level and people' s health education level, and main- taining a good mood.
出处 《中国当代医药》 2013年第9期174-176,179,共4页 China Modern Medicine
关键词 类风湿关节炎 生活质量评价 生活质量 影响因素 Rheumatoid arthritis Quality of life evaluation Quality of life Influential factor
  • 相关文献

参考文献13

二级参考文献43

共引文献224

同被引文献72

  • 1徐丽玲,詹思延,李俊.生活质量评价在类风湿关节炎及其疗效评价中的应用[J].中华风湿病学杂志,2004,8(10):633-635. 被引量:13
  • 2王志稳,张燕文,万巧琴,郑群怡.类风湿关节炎患者的生活质量及相关医学应对方式[J].中国实用护理杂志(下旬版),2006,22(5):6-8. 被引量:19
  • 3菲尔斯坦.凯利风湿病学[M].粟占国,译.8版.北京:北京大学医学出版社.2011:1089.
  • 4Tukowi J,Chlatdek J,Hroch M,et al.677TT genotype is associated with elevated risk ofmethotrexate ( MTX ) toxicity in juvenile idiopathic arthritis:treatment outcome,erythrocyte concentrations of MTX and fo-lates,and MTHFR polymorphisms [ J ] .J Rheumatol, 2010,37 (10) :2180-2186.
  • 5Nishimoto N,Hashimoto J, Miyasaka N.Study of active controlled monotherapy used for rheumatoid arthritis,an IL-6 inhibitor ( SAMURAI ) :evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlld trial of tocilizumab [J].Ann Rheum Dis,2007,66 ( 9 ) :1162-1167.
  • 6Cutolo M,Sulli A,Pizzorni C,et al.Anti-inflammatory mecha-nisms of methotrexate in rheumatoid arthritis[ J ]. Ann Rheum Dis,2001,60 ( 8 ) :729-735.
  • 7Tian H,Cronstein BN.Understanding the mechanism of action of methotrexate:implications for the treat- ment of rheumatoid arthritis [ J ] .Bull NYU Hosp Jt Dis,2007,65 ( 3 ) :168-173.
  • 8Luo Q,Sun Y,Liu W,et al.A Novel Disease-Modifying Antirheumatic Drug,Iguratimod,Ameliorates Mu- rine Arthritis by Blocking IL-17 Signaling,DIStinct from Methotrexate and Leflunomide [ J ] .J Immu- nol,2013,191 (10) :4969-4978.
  • 9Singh JA,Furst DE,Bharat A,et al.2012 update of the 2008 American College of Rheumatology recommen- dations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheuma- toid arthritis [ J ].Arthritis Care Res( Hoboken ),2012,64 ( 5 ) :625-639.
  • 10Smolen JS,Landewe R,Breedveld FC,et al.EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modify- ing antirheumatic drugs:2013 update [ J ] .Ann Rheum Dis,2014, 73 ( 3 ) :492-509.

引证文献5

二级引证文献61

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部